Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines

Michael S. Kopreski, Allan Lipton, Harold A. Harvey, Rakesh Kumar

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The p185HER2 oncogene is associated with poor prognosis in patients with breast cancer. Both anti-p185HER2. MAb and cytokines have been shown to downregulate p185HER2 expression. We investigated the effect of combinations of humanized 4D5, an anti-p185HER2 MAb, and the cytokines IFN-α, IFN-γ or TNF-α on the growth of three p185HER2 positive human breast carcinoma cell lines, SK-BR-3, BT-474, and MDA-MB-453. All three cell lines were treated with IFN-α (1000 U/ml) or IFN-γ (1000 U/ml) or TNF-α (100 U/ml) with or without huMAb 4D5 (100 μM), and cell growth was determined on days 3-7. While IFN-α, IFN-γ. TNF-α, and huMAb 4D5 all inhibited growth, an apparently additive inhibitory effect occurred using combinations of huMAb 4D5 plus cytokine, with huMAb 4D5 plus TNF-α causing the greatest growth inhibition. These results demonstrate the potentiation of growth inhibition of breast cancer cell lines by the combination of anti p185HER2 MAb and cytokines, and suggest that combinations of anti-growth factor receptor MAb and cytokines may be useful in the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)433-436
Number of pages4
JournalAnticancer Research
Volume16
Issue number1
StatePublished - Jan 1 1996

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Growth inhibition of breast cancer cell lines by combinations of anti-P185<sup>HER2</sup> monoclonal antibody and cytokines'. Together they form a unique fingerprint.

Cite this